Compare IKT & OEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | OEC |
|---|---|---|
| Founded | 2008 | 1862 |
| Country | United States | Luxembourg |
| Employees | N/A | 1639 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.9M | 301.8M |
| IPO Year | 2020 | 2014 |
| Metric | IKT | OEC |
|---|---|---|
| Price | $1.65 | $5.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 4 |
| Target Price | $5.55 | ★ $6.31 |
| AVG Volume (30 Days) | ★ 559.3K | 367.5K |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | ★ 1.55% |
| EPS Growth | ★ 57.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,806,700,000.00 |
| Revenue This Year | N/A | $0.09 |
| Revenue Next Year | $33.33 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.33 | $4.35 |
| 52 Week High | $2.61 | $8.64 |
| Indicator | IKT | OEC |
|---|---|---|
| Relative Strength Index (RSI) | 25.79 | 31.37 |
| Support Level | $1.59 | $4.53 |
| Resistance Level | $1.74 | $6.12 |
| Average True Range (ATR) | 0.11 | 0.25 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 4.85 | 2.03 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Orion SA is a manufacturer of carbon black products. Carbon black is a powdered form of carbon used to create the desired physical, electrical, and optical qualities of various materials. The company's operating segments are Specialty Carbon Black and Rubber Carbon Black. It generates maximum revenue from the Rubber Carbon Black segment. The Rubber Carbon Black segment is used in the reinforcement of rubber in tires and mechanical rubber goods. The Specialty Carbon Black segment is used as pigments and performance additives in coatings, polymers, printing, and special applications. Geographically, it derives a majority of its revenue from Germany.